Cargando…
Review of biologics, biosimilars, and intended copies in rheumatology, and current practice in Iraq
Biologic therapies are an important option in the treatment of patients with rheumatic disease. As the development of potential biosimilars increases, many countries are following the guidelines developed by the WHO, European Medicines Agency, or US Food and Drug Administration to create country-spe...
Autores principales: | Al Ani, Nizar Abdulateef, Gorial, Faiq I, Al-Sulaitti, Saad, Humadi, Jasmine Abbas, Awadh, Nabaa Ihsan, Mounir, Mohamed, Dershaby, Yasser El, Jones, Heather, Sunna, Nancy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307490/ https://www.ncbi.nlm.nih.gov/pubmed/30613169 http://dx.doi.org/10.2147/OARRR.S176965 |
Ejemplares similares
-
Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries
por: El Zorkany, Bassel, et al.
Publicado: (2018) -
Clinical Outcomes in Iraqi Patients with Rheumatoid Arthritis Following Earlier or Later Treatment with Etanercept
por: Al-Ani, Nizar, et al.
Publicado: (2021) -
A case report of an extremely rare association of ankylosing spondylitis with pachydermoperiostosis
por: Gorial, Faiq I., et al.
Publicado: (2023) -
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
por: Mysler, Eduardo, et al.
Publicado: (2016) -
Long-Term Adherence to Etanercept in Treatment Effectiveness of Patients with Spondyloarthritis: 7-Year Data from the Iraq National Registry
por: Younis, Ali Abdulrahman, et al.
Publicado: (2022)